- June 24, 2025– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of…
- June 5, 2025– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End…
- June 3, 2025NEW YORK, June 3, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a…
- June 2, 2025NEW YORK, June 2, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- May 29, 2025NEW YORK, May 29, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a…
- May 28, 2025NEW YORK, May 28, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a…
- May 2, 2025NEW YORK, May 2, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- April 30, 2025– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even…
- April 10, 2025NEW YORK, April 10, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a…
- April 9, 2025NEW YORK, April 9, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a…
